Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b

Intervirology

Volumn 53, Issue 1, 2010, Pages 49-54

  Sasase, Noriko ^a   Kim, Soo Ryang ^b   Kudo, Masatoshi ^c   Kim, Ke Ih ^a   Taniguchi, Miyuki ^b   Imoto, Susumu ^b   Mita, Keiji ^b   Hayashi, Yoshitake ^a   Shoji, Ikuo ^a   El Shamy, Ahmed ^a   Hotta, Hak ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE ASAHI HOSPITAL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis; Early viral dynamics; HCV RNA genotype 1b; High viral load; IFN RBV resistance determining region; PEG IFN RBV combination therapy; Virological response, prediction

Indexed keywords

HEPATITIS C ANTIGEN; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; SERUM; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 75349106114     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000252784     Document Type: Conference Paper

References (17)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
3. Nakamura H: Early prediction of sustained viral responder and non-responder during interferon and ribavirin combination therapy in chronic hepatitis C. Hepatol Res 2005; 33: 269-271.
4. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H: Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ ribavirin combination therapy. Hepatology 2008; 48: 38-47.
5. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81. (Pubitemid 26017933)
6. Akuta N, Suzuki S, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H: Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphism in the viral core protein and very early dynamics of viremia. Intervirology 2007; 50: 361-368.
7. Ferenci P: Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis. 2004; 24:S25-S31.
8. Nomura H, Miyagi Y, Tanimoto H, Higashi M, Ishibashi H: Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J Gastroenterol 2009; 44: 338-345.
9. Sasase N, Kim SR, Kim KI, Taniguchi M, Imoto S, Hotta H, Shouji I, El-Shamy A, Kawada N, Kudo M, Hayashi Y: Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b. Intervirology 2008; 51:S70-S75.
10. Davis GL: Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36: S145-S151.
11. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-107.
12. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
13. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa-2a. Gastroenterology 2001; 120: 1438-1447.
14. Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, et al: A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45: 204-213.
15. Asahina Y, Izumi N, Umeda N, Hosokawa T, Ueda K, Doi F, et al: Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat 2007; 14: 396-403.
16. Izumi N, Asahina Y, Kurosaki M, Uchihara M, Nishimura Y, Inoue K, et al: A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load. Intervirology 2004; 47: 102-107.
17. Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, et al: Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930-936.